Global Giant Papillary Conjunctivitis Market Insights Forecasts to 2030

• The Global Giant Papillary Conjunctivitis Market Size was estimated to had a significant growth in 2021.
• The market is growing at a CAGR of 5.2% from 2022 to 2030.
• The Worldwide Giant Papillary Conjunctivitis Market size is projected to reach multimillion by 2030.
• Asia Pacific is expected to grow the fastest during the forecast period.

 

The Global Giant Papillary Conjunctivitis Market Size is expected to reach a multimillion by 2030, at a CAGR of 5.2% during the forecast period 2022 to 2030. Due to the high prevalence rate, increased emphasis on R&D projects, improved reimbursement policies, and growing need for effective therapy, it is anticipated that the giant papillary conjunctivitis market would grow.

 

 Market Overview

The most severe form of mechanically induced papillary conjunctivitis, known as Giant (mechanically induced) Papillary Conjunctivitis (GPC), can occur after various mechanical shocks to the tarsal conjunctiva. Considering applying contact lenses (CLs) is primarily associated with GPC (CLPC), which can cause the upper tarsal conjunctiva to become inflamed, this condition is also known as contact lens-induced papillary conjunctivitis. Also, this condition is caused by the immune system overreacting to foreign material, such as dust, pollen, or contact lenses. Moreover, people who wear soft contact lenses get papillary reactions similar to allergic conjunctivitis. The GPC can also affect those who do not wear contact lenses. But this is rare, mostly affecting those who have artificial eyes or stitches. GPC can also affect people who don't wear contact lenses, but this is rare. The majority of those who experience this have artificial eyes or stitches. The development of enormous papillae (1.0 mm in diameter or more) on the surface of the upper tarsal gave rise to the non-infectious inflammatory syndrome known as GPC.

 

Report Coverage

This research report categorizes the global giant papillary conjunctivitis market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global giant papillary conjunctivitis market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global giant papillary conjunctivitis market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.

Driving Factors

The global giant papillary conjunctivitis market growth is the increasing usage of contact lenses is a major driver in the rising prevalence, which is driving market revenue growth. Although GPC can happen with any type of contact lens, however, it's most generally associated with using soft (hydro-gel) contacts. The prevalence of the disease depends on several factors, such as the type of contact lenses worn, the material used, how frequently they are cleaned, and how long they have been in use. Moreover, technological advancements and diagnostic tools in the ophthalmology field, such as Tandem Scanning Confocal Microscopy (TSCM), which enables users to view organisms in real-time and allows ophthalmologists to check cornea, have boosted the diagnosis rate. Also, increasing awareness about allergic conjunctivitis and its treatment options may grow the market. Furthermore, the factors driving market revenue growth include increasing healthcare spending, advancements in medical technology, higher government financing, and rising government and private organization attempts to create awareness about the condition and its prevention methods.

 

Restraining Factors

The main factor restricting market expansion is the adverse effects of prescription medications are expected to restrict the market growth. Also, Giant papillary conjunctivitis complications and high treatment costs may restrain the growth of the market. Moreover, misdiagnosis of giant papillary conjunctivitis with common eye infection due to similar symptoms and low diagnosis costs may affect the growth of the market.

 

Market Segmentation

Global Giant Papillary Conjunctivitis Market, By Type

Based on the types, the global giant papillary conjunctivitis market is bifurcated into solid dosage form, liquid dosage form, & others.

 

Global Giant Papillary Conjunctivitis Market, By Route of Administration

Based on the types, the global giant papillary conjunctivitis market is classified into an oral route, parenteral route, topical route, and others.

 

The hospital segment is leading the market over the forecast period.

Based on the end users, the giant papillary conjunctivitis market is segmented into hospitals, clinics, home care services, and others. Among these segments, the hospital segment held the largest market share due to rising the number of incidences of this disorder. Also, the expansion of hospitals and treatment have done under the supervision of medical professionals led the hospital segment during the forecast period.

 

Regional Segment Analysis of the giant papillary conjunctivitis market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is dominating the largest market share during the forecast period.

 

Get more details on this report -

Request Free Sample PDF

The North America Market is influenced by the market growth of the market due to the most of the American population is wearing contact lenses, so the incidence of increase in cases of giant papillary conjunctivitis. Furthermore, the launch of novel products, greater acceptance of novel medicines and technologies, a strong product pipeline, and rising R&D spending are a few additional variables affecting market revenue growth over the forecast period. Also, during the forecast period, the region's high healthcare spending and well-established healthcare infrastructure is influencing the growth of market share.

 

The Asia Pacific market is expected to register as the fastest-growing market due to the higher incidence of such diseases and participation in research. Moreover, increasing public health awareness and raising awareness of the treatment for large papillary conjunctivitis is expected to boost the market revenue growth in this region.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global giant papillary conjunctivitis market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Atopix Therapeutics Ltd.
• Allegran
• Ocular Therapeutix, Inc.
• Santen Pharmaceutical Co. Ltd.
• Novartis
• Boehringer Ingelheim
• Pfizer Inc
• Allegran
• Sun Pharma
• Sirion Therapeutics, Inc.
• Akorn Incorporated
• IBA Vision Ophthalmics

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments

• In May 2022, when it began trading on the New York stock exchange and Toronto stock exchange under the ticker symbol “BLCL” premier eye health company Bausch + Lomb Corporation, which is dedicated to preserving and improving the ability of sight for millions of people globally, became a publicly traded company.

 

• In October 2021, the Supplemental New Drug Application submitted by Ocular Therapeutix Inc. to add more indications for Dextenza's 0.4 mg of dexamethasone ophthalmic insert was approved. Dextenza is the first intracanalicular insert offered by a healthcare professional and FDA-approved to treat ocular discomfort brought on by allergic conjunctivitis with a single dose lasting up to 30 days.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the Global Giant Papillary Conjunctivitis Market based on the below-mentioned segments:

 

Global Giant Papillary Conjunctivitis Market, By Type

• Solid Dosage Form

• Liquid Dosage Form
• Others

 

Global Giant Papillary Conjunctivitis Market, By Route of administration

• Oral
• Parenteral Route
• Topical Route
• Other

 

Global Giant Papillary Conjunctivitis Market, By Application

• Hospitals
• Cancer Centers
• Surgical Centers
• Others

 

Global Giant Papillary Conjunctivitis Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa